Navigation Links
Mylan's Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R)
Date:3/30/2009

PITTSBURGH, March 30 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that Matrix Laboratories Limited, its India-based subsidiary in which it holds a 71.2% controlling interest, has received the first tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application (ANDA) for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg.

Mylan Vice Chairman and CEO Robert J. Coury said: "This product approval is yet another important step in providing access to a range of critical HIV medications to patients in developing countries. Mylan and Matrix continue to make a significant contribution to bringing down the cost of these vital treatments through the expansion of our high-quality anti-retroviral franchise."

Emtricitabine and Tenofovir Disoproxil Fumarate Tablets are the generic version of Gilead Sciences Inc.'s Truvada(R) Tablets. Truvada(R) is a second-line anti-HIV drug in the nucleoside reverse transcriptase inhibitor (NRTI or "nuke") family and is used in combination with other medications to control HIV infection. Patients often use second-line therapies if and when they develop resistance to initially prescribed treatments or experience clinical failures.

Matrix's wide range of ARV products includes active pharmaceutical ingredients (API) and first- and second-line finished doses. The company's emphasis on producing affordable products has allowed it to drive down the average annual cost per patient of effective therapies. Approximately 30% of HIV/AIDS patients in developing countries depend on Matrix ARV products.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test
2. BioNanomatrix Announces Issuance of Key Nanofluidics Patent Enabling Single Molecule Whole Genome Analysis
3. BioNanomatrix Receives New NCI Grant to Support Development of Chip-Based Nanofluidics Systems for Cell Fractionation
4. BioNanomatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
5. TEI Biosciences Launches SurgiMend(TM) Collagen Matrix for Soft Tissue Reconstruction
6. Collagen Matrix, Inc. Launches OssiMend(TM) Bone Graft Matrix for Orthopedic and Spine Applications
7. Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System
8. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
9. Organogenesis, Inc. Announces Acquisition of NanoMatrix, Inc.
10. Engineers make first active matrix display using nanowires
11. BioNanomatrix Named Best Management Team at the 2008 Ben Franklin Emerging Business Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... The Children’s Tumor Foundation ... that causes tumors to grow on nerves throughout the body. It affects 1 in ... numerous community events held during the month of May, as well as online activities, ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... PBI-Gordon Corporation ... and Agricultural Sales. , Doug began his career at PBI-Gordon in February 1988, ... in a wide variety of roles, ranging from customer service to national product manager, ...
(Date:5/3/2016)... 2016 The report "Biochips ... Gene Expression) Lab-on-a-chip (IVD & POC, Proteomics), ... Centers), Fabrication Technology (Microarrays, Microfluidics) - Forecast ... is expected to reach USD 17.75 Billion ... 2015, growing at a CAGR of 18.4% ...
(Date:5/3/2016)... ... 03, 2016 , ... In a list published by the Boston Business Journal, ... private companies; a small percentage of the state's 615,000+ small businesses. The list examined ... in revenue from 2012 to 2015. , As this award comes on ...
Breaking Biology Technology:
(Date:3/17/2016)... 2016 ABI Research, the leader in ... biometrics market will reach more than $30 billion ... 2015. Consumer electronics, particularly smartphones, continue to boost ... to reach two billion shipments by 2021 at ... , Research Analyst at ABI Research. "Surveillance is ...
(Date:3/14/2016)... , Allemagne, March 14, 2016 ... http://www.apimages.com ) - --> - Renvoi : ... - --> --> ... solutions biométriques, fournit de nouveaux lecteurs d,empreintes digitales ... LF10 de DERMALOG sera utilisé pour produire des ...
(Date:3/10/2016)... BLUE BELL, Pa. , March 10, 2016   ... U.S. Customs and Border Protection (CBP) is testing ... in San Diego to help identify ... United States . The test, designed to help determine ... outdoor, pedestrian environment, began in February and will run until ...
Breaking Biology News(10 mins):